146 related articles for article (PubMed ID: 33864020)
1. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
Eyre TA; Caillard S; Finel H; Boumendil A; Kothari J; Zimmermann H; Trappe RU; De Wilde V; Tholouli E; Kanfer E; Broom A; Damaj G; Bargetzi M; Kozák T; Hilgendorf I; Crawley C; Kerre T; Trněný M; Bachy E; Robinson S; Montoto S
Bone Marrow Transplant; 2021 Sep; 56(9):2118-2124. PubMed ID: 33864020
[TBL] [Abstract][Full Text] [Related]
2. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
[TBL] [Abstract][Full Text] [Related]
3. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
Robinson SP; Boumendil A; Finel H; Blaise D; Poiré X; Nicolas-Virelizier E; Or R; Malladi R; Corby A; Fornecker L; Caballero D; Pohlreich D; Nagler A; Thieblemont C; Finke J; Bachy E; Vincent L; Schroyens W; Schouten H; Dreger P
Bone Marrow Transplant; 2016 Mar; 51(3):365-71. PubMed ID: 26618550
[TBL] [Abstract][Full Text] [Related]
6. Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation.
Eyre TA; Barrington SF; Okosun J; Abamba C; Pearce RM; Lee J; Carpenter B; Crawley CR; Bloor AJC; Gilleece M; Nicholson E; Shah N; Orchard K; Malladi R; Townsend WM
Haematologica; 2023 Mar; 108(3):785-796. PubMed ID: 35586966
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Romero S; Montoro J; Guinot M; Almenar L; Andreu R; Balaguer A; Beneyto I; Espí J; Gómez-Codina J; Iacoboni G; Jarque I; López-Andújar R; Mayordomo-Aranda E; Montalar J; Pastor A; Pastor M; Piñana JL; Rojas-Ferrer N; Sánchez-Lázaro I; Sandoval J; Sanz G; Sanz MÁ; Solé A; Sanz J
Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
[TBL] [Abstract][Full Text] [Related]
8. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
9. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
10. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.
Tai R; Tirumani SH; Tirumani H; Shinagare AB; Hornick JL; Ramaiya NH
Br J Radiol; 2015 Aug; 88(1052):20140861. PubMed ID: 25989696
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation.
Avivi I; Boumendil A; Finel H; Nagler A; de Sousa AB; Santasusana JMR; Vandenberghe E; Afanasyev B; Bordessoule D; Moraleda JM; Garcia EC; Pohlreich D; Garcia GG; Thomson K; Or R; Beelen D; Zuffa E; Giebel S; Berthou C; Salles G; Melpignano A; Montoto S; Dreger P
Bone Marrow Transplant; 2018 Aug; 53(8):1001-1009. PubMed ID: 29463854
[TBL] [Abstract][Full Text] [Related]
12. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years.
Vergote VKJ; Deroose CM; Fieuws S; Laleman W; Sprangers B; Uyttebroeck A; Van Cleemput J; Verhoef G; Vos R; Tousseyn T; Dierickx D
Transpl Int; 2022; 35():10707. PubMed ID: 36589262
[TBL] [Abstract][Full Text] [Related]
14. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
15. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
González-Barca E; Boumendil A; Blaise D; Trněný M; Masszi T; Finel H; Michieli MG; Bittenbring JT; Gritti G; Snowden JA; Bishton M; Bruno B; de Villambrosia SG; Janikova A; Leleu X; Anagnostopoulos A; Poiré X; Crysandt M; Özkurt ZN; Vandenberghe E; Itälä-Remes M; Cahn JY; Jantunen E; Schroyens W; Maertens J; Esquirol A; Dreger P; Montoto S; Sureda A
Bone Marrow Transplant; 2020 Feb; 55(2):393-399. PubMed ID: 31541205
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
[TBL] [Abstract][Full Text] [Related]
17. The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience.
Roerden M; Walz JS; Müller MR; Sökler M; Federmann B; Kanz L; Bethge W; Vogel W
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2595-2604. PubMed ID: 31410605
[TBL] [Abstract][Full Text] [Related]
18. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
Khouri IF; Milton DR; Gulbis AM; Jabbour EJ; Nastoupil L; Ledesma C; Anderlini P; Bashir Q; Daher M; Im JS; Iyer SP; Marin D; Mehta RS; Olson AL; Popat UR; Qazilbash M; Saini N; Samaniego F; Rondon G; Medeiros LJ; Champlin RE
Clin Cancer Res; 2021 Nov; 27(21):5847-5856. PubMed ID: 34380640
[TBL] [Abstract][Full Text] [Related]
19. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
